Upcoming Biomarkers Events

Biomarkers US: In-Person

03 - 04 October 2022 |

San Diego, USA

03 - 04 October 2022

San Diego, USA

Gain a US perspective on the latest technologies and novel biomarkers driving forward translational research and precision medicine

Biomarker Analysis Europe: In-Person

01 - 02 November 2022 |

Berlin, Germany

01 - 02 November 2022

Berlin, Germany

Hear from and meet with the leading figures in biomarker analysis to explore how companies are innovating in biomarker analysis

Biomarkers for NASH Symposium

07 December 2022 |

Online: GMT (UTC+0)

07 December 2022

Online: GMT (UTC+0)

Designed to deliver the latest insights on advancing NASH therapeutic development and diagnosis through non-invasive biomarker strategies

Biomarkers UK: In-Person

27 - 28 February 2023 |

Manchester, UK

27 - 28 February 2023

Manchester, UK

Europe’s flagship event for Biomarker Research Returns: the must-attend forum to engage with the latest trends transforming biomarker and translational research

Biomarkers for NASH Symposium

June 2023 |

BST (UTC+1)

June 2023

BST (UTC+1)

More Information Coming Soon

Biomarkers US: In-Person

October 2023 |

San Diego, USA

October 2023

San Diego, USA

More Information Coming Soon

Biomarker Analysis Europe: In-Person

November 2023 |

Berlin, Germany

November 2023

Berlin, Germany

More Information Coming Soon

Upcoming Discussion Groups

Our monthly Discussion Groups are hosted by a panel of leading industry experts who explore some of the key issues facing translational research & biomarker development today.

Attendance to our Discussion Groups is available to members of our Biomarkers Member Community. For more information about Membership, please click here.

Overcoming challenges of NASH in Clinical Development

Taking place Monday 12 September 2022 | 15:00 BST (09:00 EST)

Discussion Topics:

  • Precision Medicine Biomarker Needs in NASH
  • Monitoring Biomarkers to Detect NASH Disease Development
  • Non-Invasive Biomarkers for NASH

Discussion Leaders:

  • Vincent Mikol, Precision Medicine Head at Sanofi
  • Isabella Gashaw, Principal Clinical Biomarker Lead Cardiometabolism at Boehringer Ingelheim 
  • Helen Heymann, Senior Scientific Project Manager, at Foundation for the National Institutes of Health
  • Louise Maymann Nitze, Principal Translational Medicine Scientist at Novo Nordisk
Digital Biomarkers for Disease Detection and Monitoring

Taking place Thursday 27th October | 15:00 BST (09:00 EST)

Discussion Topics:

  • Effective tracking of patient recovery
  • Overcoming the challenges in early disease detection
  • Remote monitoring of patients

Discussion Leaders:

  • Beverley Patterson, Clinical Science Director at Ono Pharma UK Ltd
  • George Kumar, Director and Medical Lead- Diagnostics & Digital Pathology at BMS
  • Steven Piccoli, Associate Vice President at Sun Pharmaceutical Advanced Research Center
Patient Engagement in Biomarker Development 

Taking place Tuesday 8 November 2022 | 15:00 GMT (11:00 EST)

Discussion Topics:

  • Patient Engagement in Biomarker Clinical Trials
  • Clinical Adoption of New Biomarkers in Patient Care
  • Awareness of Clinical Utility of Biomarker Patient Testing for New Therapeutics

Discussion Leader:

  • Christopher Conn, Scientific Director of Companion Diagnostics Strategy and Precision Medicine at AbbVie
  • George Kumar, Director and Medical Lead- Diagnostics & Digital Pathology at BMS

Reports and write-ups pertaining to previous Discussion Groups are available in our In-Depth section.

Previous Discussion Groups

June 2022 

Discussion Topics:

  • Presentation: “The Intersection between Spatial and Drug Discovery”, by Anna Lyubetskaya, Senior Principal Scientist, BMS 
  • Spatial heterogeneity and the application of spatial technology to biomarkers 
  • Advances in high-throughput ‘omics’ technologies to accelerate the pace of biomarker discovery 
  • Comprehensive molecular profiling for improved diagnostics and therapeutics 
  • Limitations of different omics platforms 

Discussion Leaders:

  • Axel Ducret, Senior Principal Scientist, Roche
  • Vilma Decman, Senior Scientific Director; Head of the Cellular Biomarkers, GSK
  • Anna Lyubetskaya, Senior Principal Scientist, BMS

May 2022

Discussion Topics:

  • Presentation: “Spatial Biology for Biomarker Discovery In Immuno-Oncology ” by Yu Liang, Director, Clinical Biomarker at Compugen 
  • Limitations of predictive biomarkers in immuno-oncology
  • Improving biomarker discovery with multiplex immunofluorescence 
  • Application of spatial biomarkers in translational and clinical research 

Discussion Leaders:

  • Yu Liang, Director, Clinical Biomarker, Compugen
  • Rajit Kolammunne, Senior Scientist BioScience, AstraZeneca
  • Vilma Decman, Senior Scientific Director; Head of the Cellular Biomarkers, GSK

April 2022

Discussion Topics:

  • Presentation: Fluid Biomarkers For Neurodegenerative Diseases“, by Jordi Clarimon, Head of Fluid Biomarkers, Lundbeck 
  • Novel fluid biomarkers for neurodegenerative diseases development and diagnosis 
  • Challenges of the field & how they could be overcome with new methodological advances 

Discussion Leader:

 Jordi Clarimon, Lead of Fluid Biomarkers, Lundbeck 

March 2022

Discussion Agenda:

  • Presentation by Kathryn Newhall, VP of Translational Clinical Development, Cellectis
  • Presentation by John Rossi, Head of Translational Medicine, SVP Research, Cero Therapeutics 
  • Panel Discussion: Translation in the Clinic

Discussion Leaders: 

  • Kathryn Newhall, VP of Translational Clinical Development, Cellectis 
  • John Rossi, Head of Translational Medicine, SVP Research, Cero Therapeutics

February 2022

Discussion Topics: 

  • How biomarkers may inform a meaningful clinical decision for a specific patient 
  • Clinical, statistical and regulatory issues in the use of biomarkers as clinical endpoints 

Discussion Leader:

  • Deepti Aurora-Garg, Executive Director Companion DiagnosticsMerck

December 2021

Flow cytometry is a powerful quantitative and preparative tool, allowing for the analytical interrogation of single cells amongst potentially millions of cells in minutes. Since its inception in 1953 and commercial popularisation in the 1970s, flow cytometry has emerged as a leading and sophisticated technology in applying the high-resolution characterisation of single cells within complex cellular networks. Challenges remain, however, and in our first biomarkers discussion group we bring together an exclusive panel of key opinion leaders to discuss the key factors behind the market’s growth, priorities, future outlook & challenges.

Discussion Points:

  • Validating flow cytometry techniques 
  • Developing high-throughput approaches & improving robustness 
  • Data management strategies, including informatics, sample delivery & AI/ML approaches 
  • Multiplexed high-throughput flow cytometry for drug discovery & repurposing 
  • Regulatory perspectives on the various barriers/challenges of flow-based testing  

Discussion Group Leaders:

  • Larry A. Sklar,
    Distinguished Professor Emeritus, University of New Mexico
  • Maria Hernandez-Fuentes,
    Head of Huma Tissue Technologies, UCB

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Member Community Login